TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Kindeva Drug Delivery Expands Manufacturing Capacity for Environmentally Friendly Inhalers at UK Facility

Monday, May 06, 2024

Kindeva Drug Delivery (Kindeva), a key player in the global market for drug-device combination products, has announced its investment in a second manufacturing line for pressurized metered-dose inhaler (pMDI) products with low-GWP (Global Warming Potential) propellants at its Loughborough, U.K., facility.

This new line is set to handle both HFA-152a and HFO-1234ze propellants, which have GWPs significantly lower than the industry standard HFA-134a. Expected to be operational by 2026, this addition comes alongside Kindeva’s first pMDI manufacturing line, which is currently in its installation phase and slated for completion later in 2024.

Kindeva, highlighted the importance of this investment, stating, “This initiative will introduce one of the first large-volume commercial green propellant lines to the contract manufacturing market, capable of delivering up to 50 million pMDI units annually. By doubling down on our commitment to low-GWP propellants, we aim to support the pharmaceutical industry's sustainability objectives without compromising patient choice.”

Driven by increasing customer demand for sustainable pMDI products and in alignment with recent F-gas legislation in the European Union, this move anticipates the phase-down of existing propellants starting in 2027 and concluding by the end of 2029.

Boyer emphasized Kindeva’s longstanding expertise in pMDIs, tracing back to its pivotal role in inventing the pMDI in 1956 and leading the transition from CFC to HFA inhalers in the 1990s. He affirmed, “As industry frontrunners, we are fully committed to championing the adoption of low-GWP propellants, ensuring a greener future for all stakeholders.”

This announcement signals a new chapter in Kindeva’s journey toward sustainable innovation in pMDIs and beyond, reinforcing its position as a trailblazer in complex drug and combination products.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit